NVS Novartis AG

  1. Stocks
  2. Healthcare
  3. NYSE: NVS

Price (delayed)

$160.16

Market cap

$303.66B

P/E Ratio

30.51

Dividend/share

$4.77

EPS

$5.25

Enterprise value

$343.1B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 83

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the ...

Highlights
The quick ratio is up by 5% since the previous quarter
The stock's P/E is 71% more than its 5-year quarterly average of 17.9 and 33% more than its last 4 quarters average of 22.9
The company's debt has surged by 51% YoY
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: http://www.novartis.com
Peers: PFE MRK JNJ TEVA

Key stats

What are the main financial stats of NVS

NVS stock price

How has the Novartis AG stock price performed over time
Intraday
-0.1%
1 week
-1.09%
1 month
11.35%
1 year
21.07%
YTD
16.17%
QTD
12.34%

Financial performance

How have Novartis AG's revenue and profit performed over time
Revenue
$57.36B
Gross profit
$42.98B
Operating income
$14.44B
Net income
$10.03B
Gross margin
74.9%
Net margin
17.5%
The company's net margin fell by 31% YoY and by 22% QoQ
The company's net income fell by 30% YoY and by 21% QoQ
NVS's operating margin is down by 19% year-on-year and by 17% since the previous quarter
NVS's operating income is down by 18% year-on-year and by 16% since the previous quarter

Price vs fundamentals

How does NVS's price correlate with its fundamentals

Growth

What is Novartis AG's growth rate over time

Valuation

What is Novartis AG stock price valuation
NVS P/E details
P/E
30.51
P/B
8.18
P/S
5.29
EV/EBIT
24.1
EV/EBITDA
N/A
EV/Sales
5.98
The stock's P/E is 71% more than its 5-year quarterly average of 17.9 and 33% more than its last 4 quarters average of 22.9
The company's EPS fell by 29% YoY and by 21% QoQ
NVS's P/B is 67% above its 5-year quarterly average of 4.9 and 17% above its last 4 quarters average of 7.0
The company's equity fell by 16% YoY and by 10% QoQ
The P/S is 18% more than the 5-year quarterly average of 4.5 and 8% more than the last 4 quarters average of 4.9

Efficiency

How efficient is Novartis AG business performance
The ROIC has declined by 41% year-on-year and by 21% since the previous quarter
Novartis AG's ROA has decreased by 38% YoY and by 23% from the previous quarter
NVS's ROE is down by 28% YoY and by 18% QoQ
The company's return on sales fell by 20% YoY and by 17% QoQ

Dividends

What is NVS's dividend history
Dividend details
DPS
$4.77
Dividend yield
2.98%
Payout ratio
90.9%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Novartis AG financials performed over time
NVS's total assets is 47% greater than its total liabilities
NVS's total liabilities is up by 27% year-on-year
NVS's total assets is up by 9% year-on-year but it is down by 4% since the previous quarter
The company's debt is 30% higher than its equity
The debt to equity has soared by 81% YoY and by 10% from the previous quarter
The company's debt has surged by 51% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.